Chargement en cours...
Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine
BACKGROUND: The treatment of ulcerative colitis (UC) can place a substantial financial burden on healthcare systems. The anti-inflammatory compound 5-aminosalicylic acid (5-ASA; mesalazine) is the recommended first-line treatment for patients with UC. In this analysis, the incremental cost effective...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BioMed Central
2011
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3146407/ https://ncbi.nlm.nih.gov/pubmed/21729262 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1472-6963-11-157 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|